Gyroscope Therapeutics Announces Launch of Initial Public Offering

0
247

LONDON– Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced that it has launched the roadshow for its initial public offering in the United States of up to 6,750,000 American Depositary Shares (“ADSs”) representing 6,750,000 ordinary shares. The initial public offering price is currently expected to be between $20.00 and $22.00 per ADS, which would result in an approximate total offering size of between $135.0 million and $148.5 million, before underwriting discounts and commissions. Gyroscope also expects to grant to the underwriters a 30-day option to purchase up to an additional 1,012,500 ADSs at the initial public offering price, less underwriting discounts and commissions. All ADSs to be sold in the proposed offering will be sold by Gyroscope. Gyroscope has applied to list its ADSs on the Nasdaq Global Select Market under the ticker symbol “VISN.”

Morgan Stanley, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”), but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

In any member state of the European Economic Area (the “EEA”) this announcement and any offering are only addressed to and directed at persons who are “qualified investors” (“Qualified Investors”) within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) high net worth entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as “relevant persons”).

This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors.